China
Africa
Explore chapters and articles related to this topic
Dermal filler complications and management
Published in Michael Parker, Charlie James, Fundamentals for Cosmetic Practice, 2022
Dermatophytes are arguably the commonest cause of fungal skin infections, and they include pathogens such as Trichophyton and Microsporum genera, causing conditions such as tinea capitis and tinea faciei. Non-dermatophytes also play a role, with fungi such as Malassezia globosa, and Candida albicans cause conditions such as pityriasis versicolor, cutaneous candidiasis, respectively.
Basic dermatology in children and adolescents
Published in Joseph S. Sanfilippo, Eduardo Lara-Torre, Veronica Gomez-Lobo, Sanfilippo's Textbook of Pediatric and Adolescent GynecologySecond Edition, 2019
Kalyani Marathe, Kathleen Ellison
Superficial fungal infections can occur anywhere on the skin, including the groin (tinea cruris), body (tinea corporis) (Figure 10.3), face (tinea faciei) (Figure 10.4), and scalp (tinea capitis). Tinea can be caused by a number of different pathogens and presents with scaly erythematous plaques, often with central clearing and a raised border. The plaques can vary in size from less than 1 cm to greater than 10 cm. They are often asymptomatic but can be pruritic. Tinea versicolor can present as hyperpigmented or hypopigmented scaling macules that commonly arise on the scalp, face, or trunk.
Dermatophytosis
Published in Mahmoud A. Ghannoum, John R. Perfect, Antifungal Therapy, 2019
Mahmoud A. Ghannoum, Iman Salem, Nancy Isham
Tinea faciei affects the nonbearded areas of the face. It may present as itchy, red poorly demarcated patches or may resemble tinea corporis with scaly, red annular plaques (Figure 15.7). It should be considered in all erythematous eruptions on the face [1]. The differential diagnosis includes rosacea, contact dermatitis, seborrheic dermatitis, lymphocytic infiltration, and discoid lupus erythematosus.
Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of dermatophytosis
Published in Journal of Dermatological Treatment, 2020
Priyanka Sharma, Mala Bhalla, Gurvinder P. Thami, Jagdish Chander
Sixty clinically diagnosed and KOH positive (septate hyphae) patients of tinea corporis, tinea cruris, or tinea faciei participated in this open-label randomized comparative study which was conducted in accordance with the institutional ethics board and the Helsinki Declaration of 1975, as revised in 1983. Patients with co-existent tinea unguium, tinea pedis, or tinea manuum, recent use of antifungal drugs or steroids in last 4 weeks, pregnant and lactating women and those with comorbidities were excluded. The skin scrapings were subjected to culture on Sabouraud’s dextrose agar (SDA). The patients were randomly allocated to three groups of 20 each using sealed envelope method. Randomization was done by a non-treating physician not performing this study. Group I patients received terbinafine 250 mg orally once daily (TERB), group II patients received itraconazole 200 mg orally once daily (ITR), and group III patients received a combination of terbinafine 250 mg orally and itraconazole 200 mg orally once daily, both taken on the same day (TERB + ITR). Duration of therapy was 3 weeks in all the groups. Same brand of drugs were given to all the patients to rule out inter-brand variability in the efficacy of treatment.
Change of dermatological practice after the COVID-19 outbreak resolves
Published in Journal of Dermatological Treatment, 2022
Chuang Gao, Baoyi Liu, Yongyi Xie, Zhouwei Wu
Patients with pet-related dermatophytoses were diagnosed as tinea corporis (25/32), tinea faciei (6/32), and tinea capitis (1/32). The most frequent causative agent of these diseases was Microsporum canis (29/32), followed by Trichophyton violaceum (2/32), and Trichophyton mentagrophyte (1/32). All patients confirmed the contact with pet in home including cat (27/32), rabbit (3/32), and dog (2/32). But only three patients reported pets had suspicious skin problems.
Nanotechnological interventions in dermatophytosis: from oral to topical, a fresh perspective
Published in Expert Opinion on Drug Delivery, 2019
Riya Bangia, Gajanand Sharma, Sunil Dogra, Om Prakash Katare
Singh and Shukla carried out a study in 500 patients who were treated with oral terbinafine (5 mg/kg/day) for maximum 4 weeks duration and reported that terbinafine was effective in treating tinea corporis, tinea faciei, and tinea cruris in 2% and 30.6% patients when given for 2 and 4 weeks, respectively. They concluded that terbinafine does not hold as potential as it did in the past in the effective treatment of dermatophytosis and demanded a need of new antifungal agents of new classes [76]. A report by Bhattacharjee and Dogra, however, argued that some relevant issues must be considered before jumping to the conclusion that effectiveness of a common antifungal agent, terbinafine, is abysmal. They highlighted that in this cohort study of 500 patients of dermatophytosis, 42% patients had used topical corticosteroids containing over-the-counter creams in the recent past and it is quite well-known that a decrease in the local cellular immunity is observed by the use of such irrational corticosteroid-antifungal-antibacterial combinations, thereby being an important reason for making dermatophytosis considerably recalcitrant [77,78]. Moreover, in this study, the use of terbinafine has not been evaluated in comparison with another standard drug, such as itraconazole in a parallel study. They also pointed out that recurrences may have been resulted due to reinfection from the family members (which were left unscreened in the study) or environment, or insufficient duration of the antifungal therapy, as was the case in the index study. An investigation was carried out in 150 patients of dermatophytosis from North India, where they reported high minimum inhibitory concentration (>2 μg/ml) for terbinafine in one, four, and three isolates of T. interdigitale, T. mentagrophytes, and T. rubrum, respectively. They noted that an increase in the values of minimum inhibitory concentration is not the sole factor behind the recurrence and also, most of these strains were not drug-resistant, hence, further supporting the point that the poor cure rate of terbinafine may not be justified by its effectiveness alone [79].